Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and D...
Guardado en:
Autores principales: | Sweeting AN, Tabet E, Caterson ID, Markovic TP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
por: Shin JH, et al.
Publicado: (2013) -
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
por: Kwon YJ, et al.
Publicado: (2021) -
Prevalence of cardiometabolic risk factors and metabolic syndrome in obese Kuwaiti adolescents
por: Boodai SA, et al.
Publicado: (2014) -
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
por: Hurt RT, et al.
Publicado: (2018) -
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)